Search
Fluvastatin
go.drugbank.com/drugs/DB01095ApprovedInvestigationalFluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynth...
Categories: Hypolipidemic Agents Indicated for HyperlipidemiaPhenolphthalein
go.drugbank.com/drugs/DB04824ApprovedWithdrawnPhenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.
Categories: Drugs for Constipation, Compounds used in a research, industrial, or household settingGaucher Disease, Type 1
go.drugbank.com/conditions/DBCOND0035324Synonyms: Gaucher Disease, Non-Neuronopathic FormCeritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalCeritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of
Viral Macrophage-Inflammatory Protein
go.drugbank.com/drugs/DB15748ExperimentalViral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus...
Veglin
go.drugbank.com/drugs/DB05890ExperimentalVeglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma. … VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigational[A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal
Serplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalMost recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953] … It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries.
Oxibendazole
go.drugbank.com/drugs/DB04910ExperimentalVet approvedOxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.
Fludrocortisone
go.drugbank.com/drugs/DB00687ApprovedInvestigationalFludrocortisone is a synthetic mineralocorticoid used in conjunction with hydrocortisone to replace missing endogenous corticosteroids in patients with adrenal insufficiency. It is functionally similar to aldosterone, the body's primary ...
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain